Examples of using Frequency categories in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
The frequency categories used are.
Adverse reactions reported are listed according to the following frequency categories.
Frequency categories are defined as follows.
Within the system organ classes, adverse reactions are listed under headings of the following frequency categories: very common(≥1/10), common(≥1/100 to< 1/10) and uncommon≥1/1,000 to< 1/100.
The frequency categories are defined using the following convention.
In the table below, since the majority of the studies were of an open nature,all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic(1,603) and prophylaxis(270) studies, by system organ class, are listed.
Frequency categories are based on information available from the metformin Summary of Product Characteristics.
Presented in Table 2, by system organ classification and frequency categories, is the list of adverse reactions with at least a suspected causal relationship, reported in clinical trials cumulatively up to Year 3 and pooled for both belatacept regimens MI and LI.
Frequency categories are defined as: very common(≥1/10); common(≥1/100 to< 1/10); uncommon≥1/1,000 to< 1/100.
The ADRs listed in Table 1are presented by system organ class and frequency categories, defined using the following convention: very common(≥ 1/10); common(≥ 1/100 to< 1/10), uncommon(≥ 1/1,000 to< 1/100) rare(> 1/10,000 to< 1/1,000) or very rare< 1/10,000.
Frequency categories below reflect combined data for the 2 doses of Eperzan, 30 mg or 50 mg weekly subcutaneously.
Within each System Organ Class,adverse reactions are listed under frequency categories of very common(≥1/10), common(≥1/100 to< 1/10), uncommon(≥1/1,000 to< 1/100), rare(≥1/10,000 to< 1/1,000), very rare(< 1/10,000) and not known cannot be estimated from the available data.
Frequency categories are based on information available from pravastatin and fenofibrate Summary of Product characteristics available in the EU.
Frequency categories were determined from the crude incidence rate reported for each adverse reaction in the pivotal clinical study N 189.
Frequency categories are based on information available from simvastatin and fenofibrate Summary of Product Characteristics available in the EU.
Frequency categories are based on information available from metformin Summary of Product Characteristics available in the European Union.
Frequency categories do not account for other factors including varying study duration, pre-existing conditions and baseline patient characteristics.
The frequency categories assigned to the adverse reactions below are estimates: for most events, suitable data for calculating incidence are not available.
Frequency categories are derived from adverse reactions and/or potentially clinically significant laboratory abnormalities, and are defined according to the following conventions.
Frequency categories are derived according to the following conventions: very common(≥ 1/10), common(≥ 1/100 to< 1/10), uncommon(≥ 1/1,000 to< 1/100), rare≥ 1/10,000 to< 1/1,000.
The frequency categories assigned to the adverse reactions are mainly based on experience from clinical trials including a total of 1,171 patients with chronic hepatitis B receiving lamivudine at 100mg.
Frequency categories are defined according to the following conventions: very common(≥ 1/10), common(≥ 1/100 to< 1/10), uncommon(≥ 1/1,000 to< 1/100), rare(≥ 1/10,000 to 1/1,000) and very rare< 1/10,000.
Frequency categories are defined using the following convention: very common(≥1/10); common(≥1/100 to< 1/10); uncommon(≥1/1,000 to< 1/100); rare(≥1/10,000 to< 1/1,000); very rare(< 1/10,000); not known cannot be estimated from the available data.
Adverse reactions in Table 1 arelisted according to MedDRA system organ class and frequency category.
The adverse drug reactions are listed by frequency category.
Frequency Category.
SOC Frequency category.
Table 1 Frequency category of adverse drug reactions reported in the phase 3 studies COMFORT-I, COMFORT-II, RESPONSE.